Journal Title：Current Hematologic Malignancy Reports

his journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hematologic malignancy.

We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as leukemia, lymphoma, myeloma, and T-cell and other lymphoproliferative malignancies. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.

本期刊旨在提供國際專家的清晰、有見地、平衡的貢獻(xiàn)，回顧與血液系統(tǒng)惡性腫瘤的診斷、治療、管理和預(yù)防相關(guān)的最重要的、最近發(fā)表的臨床發(fā)現(xiàn)。

我們通過任命國際權(quán)威人士擔(dān)任關(guān)鍵主題領(lǐng)域的分部編輯來實(shí)現(xiàn)這一目標(biāo)，例如白血病、淋巴瘤、骨髓瘤、T 細(xì)胞和其他淋巴增生性惡性腫瘤。分部編輯依次選擇主題，由頂尖專家撰寫全面的評論文章，強(qiáng)調(diào)新發(fā)展和最近發(fā)表的重要論文，并通過帶注釋的參考文獻(xiàn)列表突出顯示。國際編輯委員會審查年度目錄，推薦對其國家/地區(qū)特別感興趣的文章，并確保主題是最新的并包括新興研究。還提供該領(lǐng)域知名人物的評論。

Current Hematologic Malignancy Reports創(chuàng)刊于2006年，由Springer US出版商出版，收稿方向涵蓋ONCOLOGY - HEMATOLOGY全領(lǐng)域，此刊是中等級別的SCI期刊，所以過審相對來講不是特別難，但是該刊專業(yè)認(rèn)可度不錯，仍然是一本值得選擇的SCI期刊 。平均審稿速度 12周，或約稿 ，影響因子指數(shù)2.7，該期刊近期沒有被列入國際期刊預(yù)警名單，廣大學(xué)者值得一試。